{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:36Z","timestamp":1790812116189,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Hypertriglyceridaemia is the third most common aetiology of acute pancreatitis and a leading cause of recurrence in specialized lipid clinics. The risk of acute pancreatitis rises steeply once triglycerides exceed approximately 10 mmol\/L (\u2248885 mg\/dL). Still, clinically meaningful risk may occur at lower levels in the presence of chylomicronaemia, metabolic stress, or pregnancy. This mini-review synthesizes contemporary evidence on epidemiology, mechanistic links between triglyceride-rich lipoproteins and pancreatic injury, and the practical distinction between secondary (acquired) and genetic drivers of severe hypertriglyceridaemia. We summarize acute management strategies aimed at rapid triglyceride reduction (including insulin-based approaches and therapeutic plasma exchange in selected scenarios) and focus on long-term prevention of recurrence through lifestyle interventions, correction of secondary contributors, and triglyceride-lowering pharmacotherapy. Finally, we discuss emerging RNA-targeted therapies against apolipoprotein C-III and angiopoietin-like 3, which are reshaping prevention strategies for familial and persistent chylomicronaemia and may reduce pancreatitis burden in the highest-risk phenotypes.<\/jats:p>","DOI":"10.3390\/diseases14020047","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:19:38Z","timestamp":1769761178000},"page":"47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypertriglyceridaemia-Associated Acute Pancreatitis: Risk Stratification, Drivers, and Prevention of Recurrence"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7853-0042","authenticated-orcid":false,"given":"Federica","family":"Fogacci","sequence":"first","affiliation":[{"name":"Hypertension and Cardiovascular Risk Factors Research Centre, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40100 Bologna, Italy"},{"name":"Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum 25240, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F. G.","family":"Cicero","sequence":"additional","affiliation":[{"name":"Hypertension and Cardiovascular Risk Factors Research Centre, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40100 Bologna, Italy"},{"name":"Cardiovascular Medicine Unit, IRCCS Azienda Ospedaliero\u2013Universitaria di Bologna, 40100 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.14309\/ajg.0000000000002645","article-title":"American College of Gastroenterology Guidelines: Management of Acute Pancreatitis","volume":"119","author":"Tenner","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/2050640618755002","article-title":"Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management","volume":"6","author":"Amodio","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pan.2012.05.002","article-title":"A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose","volume":"12","author":"Lindkvist","year":"2012","journal-title":"Pancreatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/MPA.0000000000002602","article-title":"Updates from the 2025 IAP Acute Pancreatitis Guidelines","volume":"55","author":"Buxbaum","year":"2026","journal-title":"Pancreas"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.pan.2025.04.020","article-title":"IAP\/APA\/EPC\/IPC\/JPS Working Group. International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society","volume":"25","author":"Uc","year":"2025","journal-title":"Pancreatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert Consensus Decision Pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia","volume":"78","author":"Virani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1516493","DOI":"10.1155\/2020\/1516493","article-title":"A Drug-Induced Acute Pancreatitis Retrospective Study","volume":"2020","author":"Gagnon","year":"2020","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/10781552221093969","article-title":"Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update","volume":"29","author":"Goraya","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1592\/phco.2005.25.10.1348","article-title":"Propofol-Associated Hypertriglyceridemia and Pancreatitis in the Intensive Care Unit: An Analysis of Frequency and Risk Factors","volume":"25","author":"Devlin","year":"2005","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1513\/AnnalsATS.202407-781OC","article-title":"Propofol, Hypertriglycerridemia, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis","volume":"22","author":"Heybati","year":"2025","journal-title":"Ann. Am. Thor. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/08850666241265671","article-title":"Parameters Predictive of Propofol-Associated Acute Pancreatitis in Critically Ill Patients with COVID-19 Pneumonia: A Retrospective Cohort Study","volume":"40","author":"Korchemny","year":"2025","journal-title":"J. Intens. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"De Luca, C., Ciciola, P., D\u2019Errico, G., Di Taranto, M.D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Di Minno, M., and Calcaterra, I. (2025). Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review. Genes, 16.","DOI":"10.3390\/genes16111377"},{"key":"ref_15","first-page":"723","article-title":"Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an \u201cFCS score\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gubensek, J., Andonova, M., Jerman, A., Persic, V., Vajdic-Trampuz, B., Zupunski-Cede, A., Sever, N., and Plut, S. (2022). Comparable Triglyceride Reduction with Plasma Exchange and Insulin in Acute Pancreatitis\u2014A Randomized Trial. Front. Med., 9.","DOI":"10.3389\/fmed.2022.870067"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2320802","DOI":"10.1001\/jamanetworkopen.2023.20802","article-title":"Early Plasmapheresis Among Patients with Hypertriglyceridemia-Associated Acute Pancreatitis","volume":"6","author":"Cao","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.pan.2022.07.013","article-title":"Insulin or blood purification treatment for hypertriglyceridaemia-associated acute pancreatitis: A systematic review and meta-analysis","volume":"22","author":"He","year":"2022","journal-title":"Pancreatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"Alquist","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2022.11.006","article-title":"Recurrence for patients with first episode of hypertriglyceridemia-induced acute pancreatitis: A prospective cohort study","volume":"17","author":"Ding","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e093011","DOI":"10.1136\/bmjopen-2024-093011","article-title":"Prevention of recurrence of hypertriglyceridemia-associated acute pancreatitis by controlling triglyceride levels: Protocol for a multicentre, randomised controlled trial (REDUCE)","volume":"15","author":"Xu","year":"2025","journal-title":"BMJ Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108507","DOI":"10.1016\/j.pharmthera.2023.108507","article-title":"Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events","volume":"250","author":"Raschi","year":"2023","journal-title":"Pharmacol. Therap"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11883-025-01379-8","article-title":"Fibrates: Do They Still Have a Role in Therapy in 2025?","volume":"28","author":"Pirillo","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e029512","DOI":"10.1161\/JAHA.123.029512","article-title":"Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials","volume":"12","author":"Wang","year":"2023","journal-title":"J. Am. Heart Ass."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-Modifying Therapies and Risk of Pancreatitis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jacl.2018.01.008","article-title":"Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Sahebkar","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e021508","DOI":"10.1136\/bmjopen-2018-021508","article-title":"Effect of fenofibrate on plasma apolipoprotein C-III levels: A systematic review and meta-analysis of randomised placebo-controlled trials","volume":"8","author":"Sahebkar","year":"2019","journal-title":"BMJ Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Balance Investigators. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk","volume":"392","author":"Watts","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: A phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and Safety of Volanesorsen (ISIS 304801): The Evidence from Phase 2 and 3 Clinical Trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr. Atheroscl. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacl.2024.12.018","article-title":"Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria","volume":"19","author":"Tsimikas","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_38","unstructured":"U.S. Food and Drug Administration (2025, December 30). TRYNGOLZA (Olezarsen) Injection, for Subcutaneous Use: Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf."},{"key":"ref_39","unstructured":"European Medicines Agency (2025, December 30). Tryngolza (Olezarsen): EPAR\u2014Medicine Overview. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tryngolza."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sydhom, P., Al-Quraishi, B., Gohar, A., El-Shawaf, M., Shehata, N., Ataya, M., Sydhom, M., Awwad, N., Motawade, H., and Naji, N. (2025). The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis. Cardiovasc. Drugs Ther., Advance online publication.","DOI":"10.1007\/s10557-025-07798-8"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Corral, P.M., Nardelli, N., and Schreier, L. (2025). Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia. Curr. Opin. Endocrinol. Diab. Obes., Advance online publication.","DOI":"10.1097\/MED.0000000000000950"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of Vupanorsen on Non\u2013High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients with Elevated Cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Preda, A., Preda, S.D., Mota, M., Iliescu, D.G., Zorila, L.G., Comanescu, A.C., Mitrea, A., Clenciu, D., Mota, E., and Vladu, I.M. (2024). Dyslipidemia in Pregnancy: A Systematic Review of Molecular Alterations and Clinical Implications. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102252"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/1753495X15612330","article-title":"Pregnancy and ketoacidosis: Is pancreatitis a missing link?","volume":"9","author":"Frise","year":"2016","journal-title":"Obstet. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1210\/clinem\/dgaf409","article-title":"Course of Pregnancies and Occurrence of Acute Pancreatitis in Women with Chylomicronemia","volume":"111","author":"Larouche","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zheng, X., Xia, P., Yue, C., Xia, J., Zhou, Y., Chen, L., Song, Y., Gao, J., Li, N., and Li, X. (2025). A multidisciplinary management model for severe gestational hypertriglyceridemia: Using plasmapheresis to prevent pancreatitis in pregnancy. BMC Pregnancy Childbirth, 25.","DOI":"10.1186\/s12884-025-08222-7"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2024.02.052","article-title":"Diagnosis and Management of Acute Pancreatitis","volume":"167","author":"Trikudanathan","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.31128\/AJGP-01-25-7535","article-title":"Hypertriglyceridaemia: A practical approach for primary care","volume":"54","author":"Lan","year":"2025","journal-title":"Austr. J. Gen. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hegele, R.A. (2025). Approach to the Adult Patient with Chylomicronemia. J. Clin. Endocrinol. Metab., dgaf701. Advance online publication.","DOI":"10.1210\/clinem\/dgaf701"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2024.09.008","article-title":"Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America","volume":"19","author":"Hegele","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacl.2025.07.008","article-title":"Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study","volume":"19","author":"Brown","year":"2025","journal-title":"J. Clin. Lipidol."},{"key":"ref_53","unstructured":"National Lipid Association (2025, December 30). North American Familial Chylomicronemia Calculator (NAFCS Scoring Tool). Available online: https:\/\/www.lipid.org."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"117476","DOI":"10.1016\/j.atherosclerosis.2024.117476","article-title":"Validation of the familial chylomicronaemia syndrome (FCS) score in an ethnically diverse cohort from UK FCS registry: Implications for diagnosis and differentiation from multifactorial chylomicronaemia syndrome (MCS)","volume":"391","author":"Bashir","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_55","first-page":"e99233","article-title":"Acute Pancreatitis: A Narrative Review","volume":"17","author":"Sindato","year":"2025","journal-title":"Cureus"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wolfe, D., Kanji, S., Yazdi, F., Barbeau, P., Rice, D., Beck, A., Butler, C., Esmaeilisaraji, L., Skidmore, B., and Moher, D. (2020). Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231883"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00621","DOI":"10.14309\/ctg.0000000000000621","article-title":"Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised)","volume":"14","author":"Saini","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhou, J., Wang, Z., Liu, Q., Cao, L., De-Madaria, E., Capurso, G., Stoppe, C., Wu, D., Huang, W., and Chen, Y. (2024). Triglyceride-lowering therapies in hypertriglyceridemia-associated acute pancreatitis in China: A multicentre prospective cohort study. BMC Med., 22.","DOI":"10.1186\/s12916-024-03755-8"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00134-017-4722-3","article-title":"Plasmapheresis therapy has no triglyceride-lowering effect in patients with hypertriglyceridemic pancreatitis","volume":"43","author":"Miyamoto","year":"2017","journal-title":"Intensiv. Care Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/MCG.0000000000000552","article-title":"Emergent Triglyceride-lowering Therapy with Early High-volume Hemofiltration Against Low\u2013Molecular-Weight Heparin Combined with Insulin in Hypertriglyceridemic Pancreatitis","volume":"50","author":"He","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1751-2980.12659","article-title":"Continuous intravenous infusion of insulin and heparin vs plasma exchange in hypertriglyceridemia-induced acute pancreatitis","volume":"19","author":"Jin","year":"2018","journal-title":"J. Dig. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MEG.0000000000002025","article-title":"Continuous insulin therapy versus apheresis in patients with hypertriglyceridemia-associated pancreatitis","volume":"34","author":"Araz","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/08850666211054365","article-title":"Hypertriglyceridemia Induced Pancreatitis: Plasmapheresis or conservative management?","volume":"37","author":"Dichtwald","year":"2022","journal-title":"J. Intensiv. Care Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jca.21922","article-title":"Effect of TPE vs medical management on patient outcomes in the setting of hypertriglyceridemia-induced acute pancreatitis with severely elevated triglycerides","volume":"36","author":"Webb","year":"2021","journal-title":"J. Clin. Apher."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/trf.16724","article-title":"Clinical analysis of the therapeutic effect of plasma exchange on hypertriglyceridemic acute pancreatitis: A retrospective study","volume":"62","author":"Lin","year":"2022","journal-title":"Transfusion"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2020.20317","article-title":"Acute Pancreatitis","volume":"325","author":"Mederos","year":"2021","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pan.2025.01.008","article-title":"Effect of plasmapheresis versus standard medical treatment in patients with hypertriglyceridemia-associated acute pancreatitis complicated by early organ failure (PERFORM-R): Study design and rationale of a multicenter, pragmatic, registry-based randomized controlled trial","volume":"25","author":"Zhou","year":"2025","journal-title":"Pancreatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1136\/gut.2008.152702","article-title":"The early prediction of mortality in acute pancreatitis: A large population-based study","volume":"57","author":"Wu","year":"2008","journal-title":"Gut"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/2\/47\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:37:22Z","timestamp":1769762242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/2\/47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["diseases14020047"],"URL":"https:\/\/doi.org\/10.3390\/diseases14020047","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}